Back
Apellis Pharmaceuticals 10K Form
Buy
54
APLS
Apellis Pharmaceuticals
Last Price:
53.88
Seasonality Move:
8.4%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive APLS News And Ratings
See the #1 stock for the next 7 days that we like better than APLS
APLS Financial Statistics
Sales & Book Value
Annual Sales: | $75.42M |
---|---|
Cash Flow: | $-169.13M |
Price / Cash Flow: | 0 |
Annual Sales: | $1.96 |
Price / Book: | 25.66 |
Profitability
EPS (TTM): | -5.25000 |
---|---|
Net Income (TTM): | $-606.04M |
Gross Margin: | $69.79M |
Return on Equity: | -206.55% |
Return on Assets: | -69.73% |
Apellis Pharmaceuticals Earnings Forecast
Key Apellis Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 5 years for APLS is 92.54%.
- The Selling, General & Administrative Expenses for APLS have been equal to 367.49% of Gross Profit Margin.
- The Research & Development expenses have been 513.44% of Revenue.
- The Interest Expense is -5.00% of Operating Income.
- The Net Earning history of APLS is -864.72% of Total Revenues.
- Per Share Earnings over the last 10 years have been positive in 4 years.
Apellis Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Healthcare |
Current Symbol: | APLS |
CUSIP: | 03753U |
Website: | apellis.com |
Debt
Debt-to-Equity Ratio: | 0.4 |
---|---|
Current Ratio: | 4.29 |
Quick Ratio: | 3.44 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
APLS Technical Analysis vs Fundamental Analysis
Buy
54
Apellis Pharmaceuticals (APLS)
is a Buy
Is Apellis Pharmaceuticals a Buy or a Sell?
-
Apellis Pharmaceuticals stock is rated a Buy
The current Apellis Pharmaceuticals [APLS] share price is $50.30. The Score for APLS is 54, which is 8% above its historic median score of 50, and infers lower risk than normal.